NEUPERT PETER M sold $3.1M of ADPT

NEUPERT PETER M sold 124,690 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $25.15 ($25.10–$25.23, $3.14M total) across 3 trades on 2026-08-17.

Original reporting
SEC EDGAR · NEUPERT PETER M
Published Aug 20, 2026, 12:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Bearish
medium confidence
Mentioned
$ADPT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTBearishLow
01

Why it matters

The director's sale represents a $3.1M reduction in holdings, which may be interpreted by the market as a bearish indicator.

02

Market read

Insider sales are closely watched; this filing could influence short-term trading decisions on ADPT.

03

What to watch

Potential upcoming clinical data releases could offset the sale impact.

Relevance 6/10Novelty 8/10Timing: post-market filing on 2026-08-19

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$ADPTBearishMedium confidence
Context

Director Peter Neupert sold 124,690 shares for $3.14M on 2026-08-17, disclosed via Form 4.

Expected impact

Modest downside pressure over the next few days.

Evidence & confidence

The sale size is material for a mid-cap biotech and was executed at $25.15 per share, close to recent market price.

Market effects

May raise concerns among biotech investors about insider sentiment.

Limited to US biotech sector.

Minimal global impact.

Counterpoint

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Adaptive Biotechnologies Corp

    US-listed biotech company (ticker ADPT).

  • Peter Neupert

    Director of Adaptive Biotechnologies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.